Latest News

Eli Lilly Stock Slips as Hyped-Up Obesity Drug Sales Fall Short. Earnings Crush Estimates.


Eli Lilly Stock Falls as Obesity Drug Sales Disappoint. | Barron’s

Eli Lilly

stock was falling Thursday as sales in the pharmaceutical company’s much-hyped obesity drug came up short. Fourth-quarter earnings, however, did crush estimates.

Shares in

Eli Lilly

(ticker: LLY) fell 2.9% in premarket trading. Futures tracking the

S&P 500

were rising 0.5%, by comparison.

2 reasons Meta stock is exploding 20% after a whopper earnings miss

Previous article

There’s still too much risk in stock and bond markets. Earn this easy 4.5% return while you wait for stability, says trader who hit 2 big calls in 2022.

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News